Overview

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

This study will explore the drug behavior and safety following single doses of tofacitinib modified-release (MR) 11 mg and MR 22 mg in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Tofacitinib